The present disclosure provides the sequence of a Paenibacillus polymyxa preproenzyme which is the precursor of a neutral protease, expression thereof in a transformed host organism, and methods for production of the neutral protease, by recombinant means. Further, use of the recombinantly produced neutral protease is disclosed in the field of cell biology, particularly for the purpose of tissue dissociation. The disclosure also includes blends with other proteases. Further disclosed are nucleotide sequences encoding the neutral protease.

The present invention relates to a novel variant RNA polymerase sigma factor 70 (δ.sup.70) polypeptide, a polynucleotide encoding the same, a microorganism containing the polypeptide, and a method for producing L-threonine by using the microorganism.

The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminan-tium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.

The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminan-tium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynu-cleotides, antibodies, expression vectors, and host cells.

The present disclosure relates to a novel polypeptide having an ability to export an ornithine-based product, and a method for producing an ornithine-based product using the same.

Methods and constructs for RNA-guided targeting of transcriptional activators to specific genomic loci.

Provided are compositions and methods based in part on the discovery that Enterococcus faecium heterologous secreted antigen A (SagA)-produced peptidoglycan fragments are protective against enteric bacterial infections. Modified bacteria that are engineered to express heterologous SagA are provided, and are included a nutraceutical, pharmaceutical, and probiotic formulations, and as components of food products, including dairy products. The modified bacteria include modified Lactobacillus bacteria that express heterologous SagA. The disclosure includes a method that involves introducing into an individual modified bacteria of that express and secrete heterologous SagA. The disclosure provides isolated peptidoglycan fragment preparations made by a exposing a composition that contains peptidoglycan to an isolated or recombinant SagA, or to modified bacteria expressing a heterologous SagA, allowing SagA to generate the peptidoglycan fragments, and separating the peptidoglycan fragments from the composition to obtain the isolated peptidoglycan fragments or a preparation that contains them.

Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.

Provided is 3 desaturase having high enzymatic activity even at normal temperature. A polypeptide which consists of an amino acid sequence having an identity of 80% or more with the amino acid sequence represented by SEQ ID NO: 2 and has 3 desaturation activity on C20 fatty acid, and a gene thereof.